(Q34114136)

English

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Mariaelena Capone

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Giuseppe Palmieri

13

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Maria Napolitano

object named as

Maria Napolitano

2

0 references

Giuseppe Castello

object named as

Giuseppe Castello

14

0 references

Corrado Caracò

object named as

Corrado Caracò

8

0 references

Paolo Antonio Ascierto

1

object named as

Paolo A Ascierto

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Margherita Cerrone

object named as

Margherita Cerrone

11

0 references

Francesco Marincola

16

object named as

Francesco M Marincola

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

4

object named as

Ester Simeone

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Nicola Mozzillo

17

object named as

Nicola Mozzillo

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Giusy Gentilcore

5

object named as

Giusy Gentilcore

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Antonio Daponte-Codina

6

object named as

Antonio Daponte

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

9

object named as

Rosa Calemma

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Rosa De Vincenzo

12

object named as

Vincenzo De Rosa

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Egidio Celentano

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Gerardo Beneduce

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

John M Kirkwood

15

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

16 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Journal of Translational Medicine

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

76

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

16 August 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Where are we with adjuvant therapy of stage III and IV melanoma in 2009?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Adjuvant therapy of melanoma with interferon: lessons of the past decade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Control of regulatory T cell development by the transcription factor Foxp3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

5 July 2018

Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

28 October 2018

Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

28 October 2018

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

28 October 2018

Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

28 October 2018

Anti-CTL-associated antigen 4: are regulatory T cells a target?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

28 October 2018

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

28 October 2018

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

28 October 2018

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

28 October 2018

Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

28 October 2018

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2936304

28 October 2018

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/20712892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20712892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20712892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of immunotherapy with interferon-alpha on regulatory T cells in renal cell carcinoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20712892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1479-5876-8-76

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34114136&oldid=2196268377"